Tart Cherry Citrate Effervescent Tablet for Urate-Lowering Therapy in Participants With Asymptomatic Hyperuricemia

Inclusion Criteria: 1. Aged 18 to 65 years, regardless of sex; 2. Meet the diagnostic criteria for primary hyperuricemia, with serum urate levels between 420 μmol/L and 540 μmol/L (for those without comorbidities) or between 420 μmol/L and 480 μmol/L (for those with at least one of the following comorbidities: hypertension, dyslipidemia, diabetes mellitus, obesity, stroke, coronary heart disease, heart failure, or CKD stage ≥2); 3. Participants with asymptomatic hyperuricemia who have not previously received urate-lowering therapy and have no history of acute gout flares; 4. Voluntarily participate in the study and provide written informed consent. Exclusion Criteria: 1. Known allergy to any of the study medications, food products, or their components; current allergies; or known hypersensitivity; 2. Active liver disease or cirrhosis, or liver dysfunction with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels \>2 times the upper limit of normal (ULN); 3. Acute infection or active gastrointestinal ulcers; 4. History of thyroid dysfunction; 5. Estimated glomerular filtration rate (eGFR) \<60 mL/min; 6. Severe cardiac diseases, such as decompensated heart failure (NYHA class III or IV), unstable angina, or a history of myocardial infarction within the previous 12 months; 7. Renal cysts, medullary sponge kidney, or other obstructive nephropathies; 8. Rheumatoid arthritis requiring treatment or arthropathies due to other causes; 9. Current use of medications that affect urate levels, including febuxostat, allopurinol, benzbromarone, probenecid, azathioprine, 6-mercaptopurine, cyclosporine, cyclophosphamide, pyrazinamide, sulfamethoxazole, trimethoprim, theophylline, thiazide diuretics, aspirin (\>325 mg/day) or other salicylates, losartan, or intravenous colchicine; 10. Secondary hyperuricemia due to hematologic disorders, renal diseases, or radiotherapy/chemotherapy for malignancies; 11. Brain disorders with impaired judgment, or mental disorders that preclude cooperation; 12. Alcohol or substance abuse; 13. Participation in another clinical trial within the three months prior to screening; 14. Malignancy or active tuberculosis; 15. Presence of other concurrent conditions that, in the investigator's judgment, may affect the efficacy evaluation or result in poor compliance; 16. Use of glucocorticoids; 17. Any other reason that, in the investigator's judgment, makes the participant unsuitable for enrollment in this trial.